Forbes -
25 Jun 2013 18:05

Investors eyeing a purchase of Myriad Genetics, Inc. (NASD: MYGN) stock, but cautious about paying the going market price of $26.09/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2014 put at the $22 strike, which has a bid at the time of this writing of $2.00. Collecting that bid as the premium represents a 9.1% return against the $22 commitment, or a 13.7% annualized rate of retur...
Share this Article
Comment on this Article
Please to comment